Richard L Page

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Clinical practice. Newly diagnosed atrial fibrillation
    Richard L Page
    Cardiology Division, Department of Internal Medicine, University of Washington School of Medicine, Seattle 98195-6422, USA
    N Engl J Med 351:2408-16. 2004
  2. ncbi Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias
    Richard L Page
    Division of Cardiology, University of Washington School of Medicine, Seattle, Washington 98195 6422, USA
    J Cardiovasc Electrophysiol 19:172-7. 2008
  3. ncbi Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry
    Richard L Page
    Department of Internal Medicine, Cardiology Division, University of Washington School of Medicine, Seattle, 98195, USA
    Heart Rhythm 1:435-40. 2004
  4. ncbi Drug therapy for atrial fibrillation: where do we go from here?
    Richard L Page
    Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific Street, Room AA502, Health Sciences Bldg, Box 356422, Seattle 98195 6422, USA
    Nat Rev Drug Discov 4:899-910. 2005
  5. ncbi Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide
    Richard L Page
    Cardiovascular Division, Clinical Cardiac Electrophysiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, USA
    Circulation 107:1141-5. 2003
  6. ncbi Medical management of atrial fibrillation: future directions
    Richard L Page
    Department of Internal Medicine Cardiology Division, University of Washington School of Medicine, Seattle, Washington 98195 6422, USA
    Heart Rhythm 4:S91-4. 2007
  7. ncbi Sympathoexcitation is attenuated during low level lower body negative pressure in subjects who develop pre-syncope
    Stephen L Wasmund
    Department of Cardiology, University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Clin Auton Res 13:208-13. 2003
  8. ncbi Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects
    Stephen L Wasmund
    University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, Dallas, TX 75390-9047, USA
    Circulation 107:2011-5. 2003
  9. ncbi Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response
    Richard L Page
    Department of Medicine, Cardiovascular Division, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas, Tex 75390 9047, USA
    Am Heart J 143:643-9. 2002
  10. ncbi Poor baroreflex gain is a marker of heightened sympathetic activity post-tachycardia termination in humans
    Robert C Kowal
    Division of Cardiology, Dept. of Internal Medicine, University of Texas, Southwestern Medical Center, Room C57.102, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA
    Clin Auton Res 13:443-6. 2003

Detail Information

Publications60

  1. ncbi Clinical practice. Newly diagnosed atrial fibrillation
    Richard L Page
    Cardiology Division, Department of Internal Medicine, University of Washington School of Medicine, Seattle 98195-6422, USA
    N Engl J Med 351:2408-16. 2004
  2. ncbi Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias
    Richard L Page
    Division of Cardiology, University of Washington School of Medicine, Seattle, Washington 98195 6422, USA
    J Cardiovasc Electrophysiol 19:172-7. 2008
    ..This study was designed to confirm efficacy of 125 mg daily azimilide...
  3. ncbi Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry
    Richard L Page
    Department of Internal Medicine, Cardiology Division, University of Washington School of Medicine, Seattle, 98195, USA
    Heart Rhythm 1:435-40. 2004
    ..We postulated that the pattern of death would be nonrandom with respect to temporal variables...
  4. ncbi Drug therapy for atrial fibrillation: where do we go from here?
    Richard L Page
    Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific Street, Room AA502, Health Sciences Bldg, Box 356422, Seattle 98195 6422, USA
    Nat Rev Drug Discov 4:899-910. 2005
    ..In this review we describe present-day medical options and developments of future therapies to treat atrial fibrillation and maintain normal sinus rhythm...
  5. ncbi Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide
    Richard L Page
    Cardiovascular Division, Clinical Cardiac Electrophysiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, USA
    Circulation 107:1141-5. 2003
    ....
  6. ncbi Medical management of atrial fibrillation: future directions
    Richard L Page
    Department of Internal Medicine Cardiology Division, University of Washington School of Medicine, Seattle, Washington 98195 6422, USA
    Heart Rhythm 4:S91-4. 2007
    ..It is hoped that efforts to develop new drugs, including those with preferential effects on the atrium, will provide therapy with greater efficacy and safety...
  7. ncbi Sympathoexcitation is attenuated during low level lower body negative pressure in subjects who develop pre-syncope
    Stephen L Wasmund
    Department of Cardiology, University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Clin Auton Res 13:208-13. 2003
    ..Our findings suggest that subjects with LBNP induced pre-syncope might have an impairment in the cardiopulmonary baroreflex gain function in the setting of a preserved arterial baroreflex gain...
  8. ncbi Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects
    Stephen L Wasmund
    University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, Dallas, TX 75390-9047, USA
    Circulation 107:2011-5. 2003
    ..Our findings suggest that restoring NSR or regularity might be beneficial, particularly in patients with heart failure...
  9. ncbi Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response
    Richard L Page
    Department of Medicine, Cardiovascular Division, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas, Tex 75390 9047, USA
    Am Heart J 143:643-9. 2002
    ..Its effect on paroxysmal supraventricular tachycardia (PSVT) has not been reported...
  10. ncbi Poor baroreflex gain is a marker of heightened sympathetic activity post-tachycardia termination in humans
    Robert C Kowal
    Division of Cardiology, Dept. of Internal Medicine, University of Texas, Southwestern Medical Center, Room C57.102, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA
    Clin Auton Res 13:443-6. 2003
    ..04). Increased sympathetic activity following tachycardia termination could be arrhythmogenic and might play a role in the genesis of recurrent ventricular arrhythmias following tachycardia termination...
  11. ncbi Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers
    Theodore S Takata
    University of Texas Southwestern Medical Center and Dallas Veterans Affairs Medical Center, Dallas, Tex 75390-9047, USA
    Circulation 106:1500-4. 2002
    ..CONCLUSIONS: Paxil decreases arterial BRS but does not prevent the presyncope associated with LBNP. The effect of Paxil on the autonomic reflexes in patients with neurally mediated syncope remains unclear...
  12. ncbi Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia
    Zachary D Goldberger
    Department of Internal Medicine, University of Washington Medical Center, VA Puget Sound Health Care System, Seattle, Washington, USA
    Am J Cardiol 101:1456-66. 2008
    ....
  13. ncbi Wenckebach periodicity at rest that normalizes with tachycardia in a family with a NKX2.5 mutation
    Warren Guntheroth
    Division of Cardiology, Department of Pediatrics, University of Washington, Seattle, Washington, USA
    Am J Cardiol 110:1646-50. 2012
    ..5. In addition, the physiology of WP is reviewed in these subjects and in highly conditioned athletes. In conclusion, the investigators report familial stable WP and ventricular noncompaction caused by a mutation in NKX2.5...
  14. ncbi Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design
    Mohamed H Hamdan
    Department of Internal Medicine, Division of Cardiology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132 2401, USA
    Pacing Clin Electrophysiol 29:1081-8. 2006
    ..Patients_enrollment will begin in summer 2006 and is expected to be completed in 2008. The results of this trial should help define the best treatment option for this common arrhythmia in patients with left ventricular dysfunction...
  15. ncbi Asymptomatic atrial fibrillation
    Robert W Rho
    Department of Medicine (Division of Cardiology, University of Washington School of Medicine, Seattle, WA, 98195-6422, USA
    Prog Cardiovasc Dis 48:79-87. 2005
    ..This manuscript provides an overview of the clinical entity of asymptomatic AF including the epidemiology, clinical significance, and the implications it has on the daily management of patients suffering from AF...
  16. ncbi Public access defibrillation
    Robert W Rho
    Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
    Heart Fail Clin 7:269-76, ix. 2011
    ..This article discusses the technologic features of the modern AED and the current data available on the use of AEDs in public settings...
  17. ncbi Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service
    Jian Ming Li
    Division of Cardiology, Department of Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN 55417, USA
    Clin Cardiol 31:538-41. 2008
    ..Arrhythmias are reported during pregnancy, although hospitalization for these infrequent events is not fully characterized. The frequency and outcome of arrhythmias during pregnancy are unknown...
  18. ncbi Pharmacological therapy of atrial fibrillation
    Kristen K Patton
    University of Washington Medical Center, Division of Cardiology, 1959 NE Pacific Street, Box 356422, Seattle, WA 98122, USA
    Expert Opin Investig Drugs 16:169-79. 2007
    ..This review concentrates on both the classical and novel pharmacological therapies aimed at maintaining sinus rhythm...
  19. ncbi Biphasic versus monophasic shock waveform for conversion of atrial fibrillation
    Robert W Rho
    The University of Washington School of Medicine, Seattle, WA 98195 6422, USA
    Card Electrophysiol Rev 7:290-1. 2003
    ..We recommend starting with biphasic energy of 100 J for atrial fibrillation of less than 48 hours duration, but using higher energies (150 J, 200 J or greater) when AF has been present for longer periods...
  20. ncbi American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the America
    Jeffrey J Goldberger
    American Heart Association, Public Information, Dallas, TX 75231-4596, USA
    Circulation 118:1497-1518. 2008
  21. ncbi Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial
    Richard L Page
    Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9047, USA
    J Am Coll Cardiol 39:1956-63. 2002
    ..This study compared a biphasic waveform with a conventional monophasic waveform for cardioversion of atrial fibrillation (AF)...
  22. ncbi Effects of resynchronization therapy on sympathetic activity in patients with depressed ejection fraction and intraventricular conduction delay due to ischemic or idiopathic dilated cardiomyopathy
    Mohamed H Hamdan
    University of Texas Southwestern Medical Center, and Dallas Veterans Affairs Medical Center, Dallas, Texas 75216, USA
    Am J Cardiol 89:1047-51. 2002
    ..If the current findings are also present with chronic biventricular pacing, then this form of therapy may have a positive impact on mortality...
  23. ncbi The automated external defibrillator
    Robert W Rho
    University of Washington School of Medicine, Seattle, Washington 98195 6422, USA
    J Cardiovasc Electrophysiol 18:896-9. 2007
    ..We encourage widespread implementation of PAD programs and enhanced public awareness about basic life support, with the expectation that such efforts will enhance survival of out of hospital cardiac arrest...
  24. ncbi Pharmacological therapy for atrial fibrillation: current options and new agents
    Mohan N Viswanathan
    University of Washington, Division of Cardiology Cardiac Electrophysiology, Seattle, WA 98195 6422, USA
    Expert Opin Investig Drugs 18:417-31. 2009
    ..This review focuses on the current and potential future pharmacological agents directed at rhythm control and maintenance of sinus rhythm...
  25. ncbi Diabetes mellitus, glycemic control, and risk of atrial fibrillation
    Sascha Dublin
    Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101 1448, USA
    J Gen Intern Med 25:853-8. 2010
    ..Diabetes may be an independent risk factor for atrial fibrillation. However, results from prior studies are in conflict, and no study has examined diabetes duration or glycemic control...
  26. ncbi Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
    Stefan H Hohnloser
    J W Goethe University, Department of Cardiology, Frankfurt, Germany
    J Cardiovasc Electrophysiol 19:69-73. 2008
    ..There is a continued need for new antiarrhythmic drugs to treat the ever-increasing number of patients with this arrhythmia. Dronedarone is a new antiarrhythmic compound currently being developed for treatment of AF...
  27. ncbi ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Societ
    Douglas P Zipes
    Eur Heart J 27:2099-140. 2006
  28. ncbi ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com
    Douglas P Zipes
    J Am Coll Cardiol 48:e247-346. 2006
  29. ncbi ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Comm
    Valentin Fuster
    J Am Coll Cardiol 48:854-906. 2006
  30. ncbi ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice
    Valentin Fuster
    Circulation 114:e257-354. 2006
  31. ncbi The automated external defibrillator: critical link in the chain of survival
    Karthik Ramaswamy
    Division of Cardiovascular Medicine (Clinical Cardiac Electrophysiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA
    Annu Rev Med 54:235-43. 2003
    ..Use of the AED by trained nontraditional first responders (e.g., firefighters, police officers, flight crews) has improved survival rates in a variety of settings and forms the basis for public-access defibrillation...
  32. ncbi ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Commi
    Valentin Fuster
    American College of Cardiology, Bethesda, MD 20814, USA
    Eur Heart J 27:1979-2030. 2006
  33. ncbi Early recurrence of atrial fibrillation: does the shock waveform matter?
    Jose A Joglar
    J Cardiovasc Electrophysiol 15:898-900. 2004
  34. ncbi Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation
    Edward L C Pritchett
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 92:941-6. 2003
    ..Adverse effects leading to withdrawal were higher in the propafenone SR 425-mg twice daily group than in any other group. Thus, propafenone SR has important and statistically significant antiarrhythmic effects in patients with AF...
  35. ncbi Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials
    Stuart J Connolly
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am Heart J 146:489-93. 2003
    ..There was another effect of azimilide: an average reduction of 0.38 symptoms (P <.01) that was independent of heart rate. CONCLUSION: Azimilide (125 mg/day) reduces the number of symptoms reported at the time of AF recurrence...
  36. ncbi Antiarrhythmic drugs for all patients with an ICD?
    Richard L Page
    JAMA 295:211-3. 2006
  37. ncbi Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm
    Edward L C Pritchett
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 151:1043-9. 2006
    ..In patients with atrial fibrillation, it has shown excellent efficacy in some previous trials and minimal efficacy in others...
  38. ncbi Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks
    Eleanor B Schron
    Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 105:589-94. 2002
    ..Adverse symptoms were associated with reduced self-perceived QoL in both groups, and sporadic shocks were associated with reduced QoL in ICD recipients...
  39. ncbi Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation
    Edward L C Pritchett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Pharmacol 42:388-94. 2002
    ..It was concluded that in patients with a history of atrial fibrillation or flutter, azimilide was associated with statistically significant increases in RR, QT, QTc(Bazett), and QTc(Fridericia) when patients were in sinus rhythm...
  40. ncbi Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease
    Charles R Kerr
    St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Cardiol 98:215-8. 2006
    ..56, p=0.11), and overall group (hazard ratio 1.22, 95% confidence interval 1.00 to 1.49, p=0.053). No patient died. In conclusion, azimilide showed a nonsignificant trend toward efficacy in maintaining sinus rhythm in patients with AF...
  41. ncbi ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline
    Andrew E Epstein
    Circulation 117:e350-408. 2008
  42. ncbi ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline
    Andrew E Epstein
    J Am Coll Cardiol 51:e1-62. 2008
  43. ncbi ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities
    Andrew E Epstein
    Heart Rhythm 5:e1-62. 2008
  44. ncbi ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary
    Andrew E Epstein
    Heart Rhythm 5:934-55. 2008
  45. ncbi American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the America
    Jeffrey J Goldberger
    J Am Coll Cardiol 52:1179-99. 2008
  46. ncbi Automated external defibrillator use by police responders: where do we go from here?
    Jose A Joglar
    Circulation 106:1030-3. 2002
  47. ncbi Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks
    Andrea M Russo
    University of Pennsylvania Health System, Presbyterian Medical Center, Philadelphia, PA 19104, USA
    Circulation 108:67-72. 2003
    ..Previous studies have shown racial differences in risk of sudden death in patients with ischemic heart disease...
  48. ncbi 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    Elliott M Antman
    J Am Coll Cardiol 51:210-47. 2008
  49. ncbi 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines
    Spencer B King
    J Am Coll Cardiol 51:172-209. 2008
  50. ncbi ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideli
    Lee A Fleisher
    Circulation 113:2662-74. 2006
  51. ncbi ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee fo
    Valentin Fuster
    France
    Europace 8:651-745. 2006
  52. ncbi ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideli
    Lee A Fleisher
    J Am Coll Cardiol 47:2343-55. 2006
  53. ncbi New-onset paroxysmal atrial fibrillation: is permanence inevitable?
    Kristen K Patton
    Am Heart J 149:388-90. 2005
  54. ncbi Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review
    Finlay A McAlister
    The University of Alberta Evidence based Practice Center, Edmonton, Alberta, Canada
    JAMA 297:2502-14. 2007
    ..Atrial-synchronized biventricular pacemakers (cardiac resynchronization therapy [CRT]) received US Food and Drug Administration (FDA) approval for use in selected patients with LV systolic dysfunction in 2001...
  55. ncbi [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]
    Valentin Fuster
    Rev Port Cardiol 26:383-446. 2007
  56. ncbi Short QT: when does it matter?
    Mohan N Viswanathan
    Circulation 116:686-8. 2007
  57. ncbi Relation of echocardiographic wall motion score index and response to dobutamine stress to defibrillation threshold at the time of implantation of a cardiac defibrillator
    Ali M Kizilbash
    University of Texas Southwestern Medical Center, USA
    Am J Cardiol 95:1099-101. 2005
    ..A WMSI at rest of > or = 2.5 had a 71% positive predictive value and an 83% negative predictive value for a DFT > or = 15 J. An ischemic or biphasic response during DSE did not predict a greater DFT at implantation...
  58. ncbi 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaborat
    Elliott M Antman
    Circulation 117:296-329. 2008
  59. ncbi Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial
    Peter J Zimetbaum
    Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Boston, Mass 02215, USA
    Circulation 110:766-9. 2004
    ..We assessed the prognostic significance of ECG markers of conduction abnormalities and left ventricular hypertrophy in the Multicenter Unsustained Tachycardia Trial (MUSTT)...
  60. ncbi 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence an
    Spencer B King
    Circulation 117:261-95. 2008